 |
| Dr. Shile Huang's Selected Publications |
|
- Houghton PJ, Huang S. mTOR as a target for cancer therapy. Curr Top Microbiol Immunol. 279:339-359, 2004.
- Huang S, Houghton PJ. Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol. 3:371-377, 2003.
- Huang S, Bjornsti MA, Houghton PJ. Rapamycins: mechanism of action and cellular resistance. Cancer Biol Ther. 2:222-232, 2003.
- Huang S, Shu L, Dilling MB, Easton J, Harwood FC, Ichijo H, Houghton PJ. Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21Cip1. Mol Cell. 11(6):1491-1501, 2003.
- Thimmaiah KN, Easton J, Huang S, Veverka KA, Germain GS, Harwood FC, Houghton PJ. Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3'-kinase-Akt signaling pathways. Cancer Res. 63:364-374, 2003.
- Huang S, Houghton PJ. Mechanisms of resistance to rapamycins. Drug Resist Updat. 4:378-391, 2001.
- Huang S, Houghton PJ. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr Opin Investig Drugs. 3:295-304, 2002.
- Huang S, Houghton PJ. Resistance to rapamycin: a novel anticancer drug. Cancer Metastasis Rev. 20:69-78, 2001.
- Huang S, Liu LN, Hosoi H, Dilling MB, Shikata T, Houghton PJ. p53/p21CIP1 cooperate in enforcing rapamycin-induced G1 arrest and determine the cellular response to rapamycin. Cancer Res. 61:3373-3381, 2001.
|
